This document provides a checklist of 22 items that should be included when reporting the results of cross-sectional studies. The checklist includes recommendations for the title, abstract, introduction, methods, results, discussion, and other sections of reports. Key elements that should be reported include the study design, setting, participants, variables, data sources, quantitative handling, statistical methods, numbers of participants, descriptive data, outcome data, estimates, subgroups, limitations, interpretation, and funding sources. Use of the checklist aims to improve transparent reporting of cross-sectional studies.
After the successful NSP 2017-2025,Goi is lauching NSP 2017-2025 for elimination of TB on 24th march( World TB day ) 2017. Module is on MOHFW site but i have try to keep it brief,hope its ll be useful specially for academic and administrative purposes.
After the successful NSP 2017-2025,Goi is lauching NSP 2017-2025 for elimination of TB on 24th march( World TB day ) 2017. Module is on MOHFW site but i have try to keep it brief,hope its ll be useful specially for academic and administrative purposes.
India being a developing country with growing population has been traditionally vulnerable to natural and man made disasters.
Development cannot be sustainable unless disaster mitigation is built into developmental process.
Disaster could be a nature calamity, outbreak of disease, bioterrorism, etc.
New Delhi, Feb 23. The health ministry has proposed a bill that seeks to empower state and local authorities to take appropriate actions to tackle public health emergencies like epidemics and bio-terrorism.
ICD-10 is a statistical classification, which means that it contains a limited number of mutually exclusive code categories, which describe all disease concepts.
The microplan is developed prior to the polio round by the Government and WHO-NPSP with support from partners at block, district and state levels. It gives a detailed plan of the house-to-house activity with team numbers, names of team members, supervisors, including influencers and routine immunization indicators.
Decentralization
Tools of Policy making
Financing Health care
Public-Private Partnership
Health Research
International Organizations
Equity
Health Reforms in Developing Countries
Stake Holders
The course offers an opportunity to develop a holistic understanding of Primary Health Care, its functions, and scope. The course attendants will learn the principles of Primary Health Care, the course is expected to help the students to understand and internalize international health and public health transition facilitating the integration of health sector with other sectors.
India being a developing country with growing population has been traditionally vulnerable to natural and man made disasters.
Development cannot be sustainable unless disaster mitigation is built into developmental process.
Disaster could be a nature calamity, outbreak of disease, bioterrorism, etc.
New Delhi, Feb 23. The health ministry has proposed a bill that seeks to empower state and local authorities to take appropriate actions to tackle public health emergencies like epidemics and bio-terrorism.
ICD-10 is a statistical classification, which means that it contains a limited number of mutually exclusive code categories, which describe all disease concepts.
The microplan is developed prior to the polio round by the Government and WHO-NPSP with support from partners at block, district and state levels. It gives a detailed plan of the house-to-house activity with team numbers, names of team members, supervisors, including influencers and routine immunization indicators.
Decentralization
Tools of Policy making
Financing Health care
Public-Private Partnership
Health Research
International Organizations
Equity
Health Reforms in Developing Countries
Stake Holders
The course offers an opportunity to develop a holistic understanding of Primary Health Care, its functions, and scope. The course attendants will learn the principles of Primary Health Care, the course is expected to help the students to understand and internalize international health and public health transition facilitating the integration of health sector with other sectors.
Literature Critique InstructionsStudents will complete and submit .docxjeremylockett77
Literature Critique Instructions
Students will complete and submit a critique of an assigned literature. A modified version of the CONSORT (Consolidated Standards of Reporting Trials) 2010 checklist will be utilized to complete and grade this assignment. Total attainable points in this assignment is 45 points which accounts for 15% of the overall course grade. Students are highly encouraged to read “CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials.” and “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomized trials.” well in advance of the literature critique due date. These articles serve as a great resource aiding in the completion of this assignment. A link to these articles as well as other resources can be found below.
Resources:
· CONSORT website: http://www.consort-statement.org/home/
· A useful resource for general background information regarding CONSORT
· Provides examples of good reporting
· Offers resources glossary of terminology, links to published literature, and more
· CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. http://annals.org/article.aspx?articleid=745807
· CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomized trials.
http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Explanation%20and%20Elaboration%20Document-BMJ.pdf
Course Number and Name
PHAR 610—Evidence Based Practice 2 Literature Critique & Journal Club
3
CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic
Item No
Checklist item (each item is worth 1 point)
Reported on page No
& Line(s)
Title and abstract
1a
Identification as a randomised trial in the title
1b
Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)
Introduction
Background and objectives
2a
Scientific background and explanation of rationale
2b
Specific objectives or hypotheses
Methods
Trial design
3a
Description of trial design (such as parallel, factorial) including allocation ratio
3b
Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants
4a
Eligibility criteria for participants
4b
Settings and locations where the data were collected
Interventions
5
The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes
6a
Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
6b
Any changes to trial outcomes after the trial commenced, with reasons
Sample size
7a
How sample size was determined
7b
When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
Sequence
8a
Method used to generate the random allocation sequence
gener.
Literature Critique InstructionsStudents will complete and submit .docxcroysierkathey
Literature Critique Instructions
Students will complete and submit a critique of an assigned literature. A modified version of the CONSORT (Consolidated Standards of Reporting Trials) 2010 checklist will be utilized to complete and grade this assignment. Total attainable points in this assignment is 45 points which accounts for 15% of the overall course grade. Students are highly encouraged to read “CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials.” and “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomized trials.” well in advance of the literature critique due date. These articles serve as a great resource aiding in the completion of this assignment. A link to these articles as well as other resources can be found below.
Resources:
· CONSORT website: http://www.consort-statement.org/home/
· A useful resource for general background information regarding CONSORT
· Provides examples of good reporting
· Offers resources glossary of terminology, links to published literature, and more
· CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. http://annals.org/article.aspx?articleid=745807
· CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomized trials.
http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Explanation%20and%20Elaboration%20Document-BMJ.pdf
Course Number and Name
PHAR 610—Evidence Based Practice 2 Literature Critique & Journal Club
3
CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic
Item No
Checklist item (each item is worth 1 point)
Reported on page No
& Line(s)
Title and abstract
1a
Identification as a randomised trial in the title
1b
Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)
Introduction
Background and objectives
2a
Scientific background and explanation of rationale
2b
Specific objectives or hypotheses
Methods
Trial design
3a
Description of trial design (such as parallel, factorial) including allocation ratio
3b
Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants
4a
Eligibility criteria for participants
4b
Settings and locations where the data were collected
Interventions
5
The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes
6a
Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
6b
Any changes to trial outcomes after the trial commenced, with reasons
Sample size
7a
How sample size was determined
7b
When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
Sequence
8a
Method used to generate the random allocation sequence
gener ...
Levelwise PageRank with Loop-Based Dead End Handling Strategy : SHORT REPORT ...Subhajit Sahu
Abstract — Levelwise PageRank is an alternative method of PageRank computation which decomposes the input graph into a directed acyclic block-graph of strongly connected components, and processes them in topological order, one level at a time. This enables calculation for ranks in a distributed fashion without per-iteration communication, unlike the standard method where all vertices are processed in each iteration. It however comes with a precondition of the absence of dead ends in the input graph. Here, the native non-distributed performance of Levelwise PageRank was compared against Monolithic PageRank on a CPU as well as a GPU. To ensure a fair comparison, Monolithic PageRank was also performed on a graph where vertices were split by components. Results indicate that Levelwise PageRank is about as fast as Monolithic PageRank on the CPU, but quite a bit slower on the GPU. Slowdown on the GPU is likely caused by a large submission of small workloads, and expected to be non-issue when the computation is performed on massive graphs.
Adjusting primitives for graph : SHORT REPORT / NOTESSubhajit Sahu
Graph algorithms, like PageRank Compressed Sparse Row (CSR) is an adjacency-list based graph representation that is
Multiply with different modes (map)
1. Performance of sequential execution based vs OpenMP based vector multiply.
2. Comparing various launch configs for CUDA based vector multiply.
Sum with different storage types (reduce)
1. Performance of vector element sum using float vs bfloat16 as the storage type.
Sum with different modes (reduce)
1. Performance of sequential execution based vs OpenMP based vector element sum.
2. Performance of memcpy vs in-place based CUDA based vector element sum.
3. Comparing various launch configs for CUDA based vector element sum (memcpy).
4. Comparing various launch configs for CUDA based vector element sum (in-place).
Sum with in-place strategies of CUDA mode (reduce)
1. Comparing various launch configs for CUDA based vector element sum (in-place).
Show drafts
volume_up
Empowering the Data Analytics Ecosystem: A Laser Focus on Value
The data analytics ecosystem thrives when every component functions at its peak, unlocking the true potential of data. Here's a laser focus on key areas for an empowered ecosystem:
1. Democratize Access, Not Data:
Granular Access Controls: Provide users with self-service tools tailored to their specific needs, preventing data overload and misuse.
Data Catalogs: Implement robust data catalogs for easy discovery and understanding of available data sources.
2. Foster Collaboration with Clear Roles:
Data Mesh Architecture: Break down data silos by creating a distributed data ownership model with clear ownership and responsibilities.
Collaborative Workspaces: Utilize interactive platforms where data scientists, analysts, and domain experts can work seamlessly together.
3. Leverage Advanced Analytics Strategically:
AI-powered Automation: Automate repetitive tasks like data cleaning and feature engineering, freeing up data talent for higher-level analysis.
Right-Tool Selection: Strategically choose the most effective advanced analytics techniques (e.g., AI, ML) based on specific business problems.
4. Prioritize Data Quality with Automation:
Automated Data Validation: Implement automated data quality checks to identify and rectify errors at the source, minimizing downstream issues.
Data Lineage Tracking: Track the flow of data throughout the ecosystem, ensuring transparency and facilitating root cause analysis for errors.
5. Cultivate a Data-Driven Mindset:
Metrics-Driven Performance Management: Align KPIs and performance metrics with data-driven insights to ensure actionable decision making.
Data Storytelling Workshops: Equip stakeholders with the skills to translate complex data findings into compelling narratives that drive action.
Benefits of a Precise Ecosystem:
Sharpened Focus: Precise access and clear roles ensure everyone works with the most relevant data, maximizing efficiency.
Actionable Insights: Strategic analytics and automated quality checks lead to more reliable and actionable data insights.
Continuous Improvement: Data-driven performance management fosters a culture of learning and continuous improvement.
Sustainable Growth: Empowered by data, organizations can make informed decisions to drive sustainable growth and innovation.
By focusing on these precise actions, organizations can create an empowered data analytics ecosystem that delivers real value by driving data-driven decisions and maximizing the return on their data investment.
Data Centers - Striving Within A Narrow Range - Research Report - MCG - May 2...pchutichetpong
M Capital Group (“MCG”) expects to see demand and the changing evolution of supply, facilitated through institutional investment rotation out of offices and into work from home (“WFH”), while the ever-expanding need for data storage as global internet usage expands, with experts predicting 5.3 billion users by 2023. These market factors will be underpinned by technological changes, such as progressing cloud services and edge sites, allowing the industry to see strong expected annual growth of 13% over the next 4 years.
Whilst competitive headwinds remain, represented through the recent second bankruptcy filing of Sungard, which blames “COVID-19 and other macroeconomic trends including delayed customer spending decisions, insourcing and reductions in IT spending, energy inflation and reduction in demand for certain services”, the industry has seen key adjustments, where MCG believes that engineering cost management and technological innovation will be paramount to success.
MCG reports that the more favorable market conditions expected over the next few years, helped by the winding down of pandemic restrictions and a hybrid working environment will be driving market momentum forward. The continuous injection of capital by alternative investment firms, as well as the growing infrastructural investment from cloud service providers and social media companies, whose revenues are expected to grow over 3.6x larger by value in 2026, will likely help propel center provision and innovation. These factors paint a promising picture for the industry players that offset rising input costs and adapt to new technologies.
According to M Capital Group: “Specifically, the long-term cost-saving opportunities available from the rise of remote managing will likely aid value growth for the industry. Through margin optimization and further availability of capital for reinvestment, strong players will maintain their competitive foothold, while weaker players exit the market to balance supply and demand.”
1. 1
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies
Item
No Recommendation
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done
and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any pre-specified hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations,and relevant dates,including periods of recruitment,
exposure, follow-up, and data collection
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of
participants
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders,and effect
modifiers. Give diagnostic criteria, if applicable.
Data sources/
measurement
8* For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if there is
more than one group
Bias 9 Describe any efforts to address potential sources ofbias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses.If applicable,
describe which groupings were chosen and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially
eligible, examined for eligibility, confirmed eligible, included in the study,
completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and
information on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
Outcome data 15* Report numbers of outcome events orsummary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
their precision (eg, 95% confidence interval). Make clear which confounders were
adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period
Other analyses 17 Report otheranalyses done—eg analyses of subgroups and interactions,and
sensitivity analyses
2. 2
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study,taking into account sources ofpotential bias or
imprecision. Discuss both direction and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations,
multiplicity of analyses,results from similar studies,and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and,if
applicable, for the original study on which the present article is based
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is
available at www.strobe-statement.org.